Temporal dynamics of cortisol and dexamethasone prevention of benzo(a)pyrene-induced morphological transformation of Syrian hamster cells. 1982

J W Greiner, and C H Evans

The temporal aspects of the anticarcinogenic action of cortisol were investigated by measurement of the frequency of carcinogen-induced morphological transformation of Syrian hamster embryo cells relative to treatment regimen. Treatment of hamster cells with 10(-5) to 10(-11) M cortisol, dexamethasone, corticosterone, 17 beta-estradiol, progesterone, or testosterone did not result in morphological transformation. However, cortisol or dexamethasone treatment beginning 48 hr before the carcinogen caused a dose-dependent reduction in the transformation frequency associated with benzo(a)pyrene [B(a)P] or ultraviolet irradiation treatment. The frequency of B(a)P transformation was reduced 54, 66, and 84% by 10(-11), 10(-10), and 10(-9) M cortisol, respectively, without altering colony formation efficiency. Dexamethasone was equipotent as cortisol as an inhibitor of B(s)P, N-methyl-N'-nitro-N-nitrosoguanidine, or ultraviolet irradiation-induced transformation. Sex steroids, non-steroid antiinflammatory compounds, and steroids without antiinflammatory activity also reduced the transformation frequency but only at concentrations that reduced colony formation. Cortisol inhibition of transformation increased as steroid exposure occurred closer (48, 24, and 8 hr) yet prior to B(a)P treatment. In contrast, if cortisol was added simultaneously with or up to 72 hr after B(a)P, the frequency of transformation was unaffected. Dexamethasone addition after B(a)P, however, reduced the transformation frequency. Thus, physiological concentrations of cortisol when present prior to carcinogen exposure can prevent carcinogen-induced morphological transformation. The ability of cortisol to inhibit ultraviolet irradiation-induced transformation indicates that the anticarcinogenic activity may be mediated by steroid-induced cellular changes which are independent to metabolic activation of the carcinogen.

UI MeSH Term Description Entries
D007213 Indomethacin A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES. Amuno,Indocid,Indocin,Indomet 140,Indometacin,Indomethacin Hydrochloride,Metindol,Osmosin
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008647 Mesocricetus A genus in the order Rodentia and family Cricetidae. One species, Mesocricetus auratus or golden hamster is widely used in biomedical research. Hamsters, Golden,Hamsters, Golden Syrian,Hamsters, Syrian,Mesocricetus auratus,Syrian Golden Hamster,Syrian Hamster,Golden Hamster,Golden Hamster, Syrian,Golden Hamsters,Golden Syrian Hamsters,Hamster, Golden,Hamster, Syrian,Hamster, Syrian Golden,Syrian Hamsters
D011374 Progesterone The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. Pregnenedione,Progesterone, (13 alpha,17 alpha)-(+-)-Isomer,Progesterone, (17 alpha)-Isomer,Progesterone, (9 beta,10 alpha)-Isomer
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004336 Drug Antagonism Phenomena and pharmaceutics of compounds that inhibit the function of agonists (DRUG AGONISM) and inverse agonists (DRUG INVERSE AGONISM) for a specific receptor. On their own, antagonists produce no effect by themselves to a receptor, and are said to have neither intrinsic activity nor efficacy. Antagonism, Drug,Antagonisms, Drug,Drug Antagonisms
D004622 Embryo, Mammalian The entity of a developing mammal (MAMMALS), generally from the cleavage of a ZYGOTE to the end of embryonic differentiation of basic structures. For the human embryo, this represents the first two months of intrauterine development preceding the stages of the FETUS. Embryonic Structures, Mammalian,Mammalian Embryo,Mammalian Embryo Structures,Mammalian Embryonic Structures,Embryo Structure, Mammalian,Embryo Structures, Mammalian,Embryonic Structure, Mammalian,Embryos, Mammalian,Mammalian Embryo Structure,Mammalian Embryonic Structure,Mammalian Embryos,Structure, Mammalian Embryo,Structure, Mammalian Embryonic,Structures, Mammalian Embryo,Structures, Mammalian Embryonic

Related Publications

J W Greiner, and C H Evans
June 1977, International journal of cancer,
J W Greiner, and C H Evans
February 1992, Cancer letters,
J W Greiner, and C H Evans
September 1972, Journal of the National Cancer Institute,
Copied contents to your clipboard!